论文部分内容阅读
目的探讨血清肿瘤标志物卵巢癌相关抗原(CA125)、人绒毛膜促性腺激素(β-hCG)及白细胞介素-6(IL-6)联合检测在卵巢癌诊断中的价值。方法选取不同临床分期的卵巢癌患者65例、卵巢良性肿瘤患者35例和正常对照30例,采用电化学发光法测定血清CA125、β-hCG含量,用ELISA法测定IL-6水平。结果卵巢癌组患者血清CA125、β-hCG及IL-6水平均显著高于卵巢良性肿瘤组和正常对照组,差异有统计学意义(P<0.05),卵巢癌组患者β-hCG、IL-6、CA125随着临床分期的升高而递增。结论 CA125、β-hCG及IL-6均为卵巢癌的重要标志物,其含量可能与卵巢癌的发生发展有关,联合检测对于卵巢癌的早期诊断、分期及判断预后具有重要临床价值。
Objective To investigate the value of combined detection of serum tumor markers ovarian cancer associated antigen (CA125), human chorionic gonadotropin (β-hCG) and interleukin-6 (IL-6) in the diagnosis of ovarian cancer. Methods Sixty-five patients with ovarian cancer with different clinical stages, 35 patients with benign ovarian tumor and 30 normal controls were enrolled in this study. The levels of serum CA125 and β-hCG were measured by the electrochemical method and the levels of IL-6 were measured by ELISA. Results The levels of serum CA125, β-hCG and IL-6 in ovarian cancer patients were significantly higher than those in benign ovarian tumors and normal controls (P <0.05). The levels of β-hCG, IL- 6, CA125 increased with the clinical staging. Conclusions CA125, β-hCG and IL-6 are both important markers of ovarian cancer. The content may be related to the development of ovarian cancer.